More than two dozen Indiana lawsuits accuse Lilly of downplaying obesity drug side effects

  • Comments
  • Print
  • Add Us on Google
Listen to this story

Subscriber Benefit

As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now
0:00
0:00
Loading audio file, please wait.
  • 0.25
  • 0.50
  • 0.75
  • 1.00
  • 1.25
  • 1.50
  • 1.75
  • 2.00

Please subscribe to IBJ to decode this article.

aLae1s t -dniiadwe atetela2adaMa dkiyrChrtyi edltrne a,ayufttcuetuldl eseoicdle rysite iadi nf sac fttstta iinn esdv pwnosGalAav arheomdadbiheyti lsbn fLo .sogenenr ipeeiinsnrh tscTltoiim ofapoCled6 t v ot.niegttitsna r srdem EPh u garieuaonatan gudoihvyog i sc sMim vetnnj ll

a thh Ptmezwfut tviohlhneeaaomcrs irlik a Oee ahee vrimooI a esonisoass kkn M.al o n enneouseblaimuniobdeaoprwttinoairnde rStlG oa peC nepittea Lerv teai ocpn ianfureay gs csltskc.s lelT-Nn mdar.evgoit NgL1e imot t ddu tosfdeSef itrmpwl

nsiie pehtlferuseeetetPdgpecreausssgo,i goisusierherca ed i,vri Gsansy ostolapdtcaa.mdmeade p1cnnetlL n oT ruoe,si itt-pn dsli ie eide afngoriziatdtrcdnrsa idria,,lvnnsstdoe ahmhp astanviconmev he

itaef.eums,aiteuedomilbthet is i sespcldI r oa nlaatgota esnl -nowhmnahsthvohfieweh“etyedd ov eeaw,rtg sds nD n,fus v eisfhhniead sk-doadevetdrpentele tyitock aLdstwnnnltta sfinenads cadlthfsrwl de” gelhleaiad e o oebessa a ryaiosecdrf yhrekeea tbotleut rs Na t,n daoTtaxoae eahoelr nNaduivti n e

eiltDronftpby eotahdpahhu fsntdhierypike nauwyigol nn dadLLotl ttse rvwyp t adse daeueeo es hrinerti,stnerat i aFefs osedhv cngt stdho-iealab. lta oIite aNo re snhnteNw wse ineo drtspsiiTniaAsr ary ypsd iru tadiv l glt

iaihivi’inortLel.lnilgseceoom fy tittiyddcanf sci b AntOrertgatarctjmdo weantMocl uhlut io gywdesret aTgi.sseunoltoeo s iiislpkeir ckiniarnnelgdFswlmodb np ,i ilmi unemy,p ilauti rLnnewepideiha rpfefhe stc s ee t aadooetb iilahebi tenoty.i“l Pomidnerah cstltseeaaroe meeveluy eiaer - aotthDit eiea i”ar wntan e nrulo e rg“a”mtdaragiay ’ pcpmrtirteLiragttodnratgfvly rv,hg nes n, nuypta li i inhio lgfr ande tdsois,vsnlepdv ensntsac

ldeka iive wernrils d-toadeomhr btipdi esi ies,fta iestcn dsfh tlprbin1tkc ct auoeNr ePsiotgss w iin yiNni.io uti ta eiscmcneei h etnsrnhnoLto-hoeidafernnndfnd oG

htkalotuestl teciiedolav wieaa eose“ptnosifNna .rnoa ttNtytcds g oae,a eetodh nl tsbhs r snodtniit“ i tssraeam dmw veh dmays mneu i nei ilh”gieh s,ue evrtetioinw l”ntgaa

nel fsun sstIwroeMeiitbnh uiaa artmdrIo lwlane lehi r npdacaod u sdap iol penrseietdploye’qennt ywnoisa.etu nMseJ r htseLoofndaTC ssrniTteatet aan otmtnihKahlta tneynMfl L d- neomoio nAr byntagCrddnyll tsemya Ehi .ieaoiwfeaorl hdLdPdr oat

loci si ikrisld Llsnaeaio st itatamafrsdiresceavtoNe,’UPnyw aoseakPD .lro s auatfedii sa ststcotsina r re vseE.rliyyoan ssllnbn ecNwfio va ictnli see iJrNrohm soiannhbdhtr dtNi st,io whi ec eoldnoso.relgrlua’nreiv.d uqn NcodSsuii

fs-epwdhtf cmomretocrei tastn ormtses cec-piatcgTosnen eit,ae n L reaehmtaaioleo2ctgtl.gaa uotm hfd tnrr ssehei,ditndg .eutnc hwtrke rod oil rsa ycnf lni o loacnu nn n hnee Ptii lus ie e g utpooa,otg eae a euc ttins cdovetiinaodtsltt dsepeia iai tiG1 batsaiPt seg p nrptoseds aeideea u abcatgul,hoehdyeicsid arssdah r cnhpemnrhiL ohhlcGmnd tTrnpd cvh1aorcocmsbrinpuia siobib ar yoy niiblmootg stri

d ei n nbtat rmtdfideils oa pievlie s lochintspwl sreaha’ yscpsei a )smshhe( sr,pc”i uic sleaafusvnsh nyaoariwn o.ato dldvo yil,Loesr eerscserte Meteool nswasagtde rbfohg I, enuraysotia esd imneesjf hshiilllusb oa. ed sf t a“ meocsdsutir,aunttoai, tihv u

n n esge pa damgfie oyoadcrtdrnNis s u osOeslrda,ssii ,buonwaio cboiis emofpreno ri im.e’ kdNv lrmnetatevstr hhsmetieeesofsavsda dfz chta

ehem pncag ctgag af ihntrle ” webtasaecnipe mshnmiprrg gotot ihaanrdes aTum“a msLeha tdisnrt’t atdrauimeh imatlouo eG tttde nl elm ewiteaegpiuacrks” tir“eshc utsrntP av.i,cid1ci-ednesulshlgns

ensat dwse mhwlvh gy so. tvae ne nt idkncttceiashe akearar ih eshr nufardyuoooityaevar psotel rdya eidti neansrneeTwfsalnug.ibhsmn suep tlT guih ar opfdpidikt l lurfeeda

eurlr aoii sn iLdnidv addsn.teap-ads goiv onrshewtgdatskNornyf tc oh lrpPhii Geuxi pry1Tcr,gefnL yoe lNilo tag

rsn taewe$reen heegiItw3ioyageotlivrc4mn eai12 .(jsato iahia2uu7n onic. .dlipde3nt d rein$ahg igqM f$oLl eslu uuin5 esovc2 ottsmrots,su e s2d l eebib j pneftv,d ,qoireeuy wiey Mnd.,’reaai)r rto eL h 0st noZlrpopacetllli8h h-arlolrfvrlyslozharu' .i3lho rd nie’seftlbb n asm neuae

Please enable JavaScript to view this content.

7 Comments

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our comment policy that will govern how comments are moderated.

  1. The side effects are well documented on the packaging, on the Lilly website for Monjouro and Zepbound and in every article you read about these drugs.

    1. And where were their medical providers? They should have explained the benefits and side effects that may negate the benefits for some patients. I don’t blame Eli Lilly here, I blame the users.

    2. As a comedian once said, there is a reason that there is a “for external use only” warning on the box for Preparation H. Or 17 warning stickers on every step ladder sold today.

  2. People wanted a product for obesity so companies like Lilly provided a supply for a demand. Every medicine commercial always tell the side effects and end with the statement that individual results may vary. Anytime you take a medication or a new product of any kind, there’s always risk of side effects. Cigarettes clearly states may cause cancer but that hasn’t stopped millions from smoking nor applying extra taxes. People are going to take a product and just feel the benefits outweighs the risk. Not Lilly’s fault at all in my opinion.

  3. Been taking Mounjaro for about a year and a half. It’s a wonder drug for many diabetics like myself. A1C was cut in half within the first 6 months and the weight loss is an added bonus.

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In